Home > News > Abraxis BioScience: A SPARC for Explosive Growth?
July 20th, 2006
Abraxis BioScience: A SPARC for Explosive Growth?
Abraxis BioScience, Inc. (ABBI) provides a unique opportunity for investment in a biopharmaceutical company that is revolutionizing cancer therapy with its proprietary nanotechnology platform. Abraxis’ nanoparticle albumin-bound, or nab technology, exploits the natural properties of a human protein, albumin, for drug delivery.
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014
Graphene industry takes further step towards commercialisation with Haydale IPO listing March 19th, 2014
Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014
Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014
Nano shake-up: UD researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery April 14th, 2014
Premier Healthcare Pitch Competition comes to Atlanta this May April 12th, 2014
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010